Literature DB >> 18385754

Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.

H Zhang1, D Trachootham, W Lu, J Carew, F J Giles, M J Keating, R B Arlinghaus, P Huang.   

Abstract

Mutation of Bcr-Abl is an important mechanism by which chronic myelogenous leukemia (CML) cells become resistant to Gleevec. The T315I mutation is clinically significant since CML cells harboring this mutation are insensitive to Gleevec and other Bcr-Abl-targeted drugs. Identification of new agents capable of effectively killing CML cells with T315I mutation would have important therapeutic implications in Gleevec-resistant CML. Here, we showed that beta-phenylethyl isothiocyanate (PEITC), a natural compound found in vegetables, is effective in killing CML cells expressing T315I BCR-ABL. Treatment of leukemia cell lines harboring wild-type or mutant Bcr-Abl with 10 microM PEITC resulted in an elevated ROS stress and a redox-mediated degradation of the BCR-ABL protein, leading to massive death of the leukemia cells. Antioxidant NAC attenuated the PEITC-induced oxidative stress in CML cells and prevented the degradation of BCR-ABL, caspase-3 activation and cell death. We further showed that the ROS-induced degradation of BCR-ABL was mediated partially by caspase-3 and the proteasome pathway. The ability of PEITC to effectively kill T315I-positive CML cells was further confirmed using primary leukemia cells isolated from CML patients. Our results suggest that PEITC is a promising compound capable of killing Gleevec-resistant CML cells through a ROS-mediated mechanism and warrants further investigations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18385754      PMCID: PMC2585768          DOI: 10.1038/leu.2008.74

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  37 in total

1.  The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.

Authors:  M Sattler; S Verma; G Shrikhande; C H Byrne; Y B Pride; T Winkler; E A Greenfield; R Salgia; J D Griffin
Journal:  J Biol Chem       Date:  2000-08-11       Impact factor: 5.157

2.  High-performance liquid chromatography-based determination of total isothiocyanate levels in human plasma: application to studies with 2-phenethyl isothiocyanate.

Authors:  L Liebes; C C Conaway; H Hochster; S Mendoza; S S Hecht; J Crowell; F L Chung
Journal:  Anal Biochem       Date:  2001-04-15       Impact factor: 3.365

3.  Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

Authors:  Jorge Cortes; Philippe Rousselot; Dong-Wook Kim; Ellen Ritchie; Nelson Hamerschlak; Steven Coutre; Andreas Hochhaus; Francois Guilhot; Giuseppe Saglio; Jane Apperley; Oliver Ottmann; Neil Shah; Philipp Erben; Susan Branford; Prasheen Agarwal; Ashwin Gollerkeri; Michele Baccarani
Journal:  Blood       Date:  2006-12-21       Impact factor: 22.113

4.  Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia.

Authors:  M Deng; G Q Daley
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

5.  Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.

Authors:  Dunyaporn Trachootham; Yan Zhou; Hui Zhang; Yusuke Demizu; Zhao Chen; Helene Pelicano; Paul J Chiao; Geetha Achanta; Ralph B Arlinghaus; Jinsong Liu; Peng Huang
Journal:  Cancer Cell       Date:  2006-09       Impact factor: 31.743

6.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 7.  Flying under the radar: the new wave of BCR-ABL inhibitors.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes
Journal:  Nat Rev Drug Discov       Date:  2007-10       Impact factor: 84.694

8.  Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.

Authors:  Heiko Konig; Nicolai Härtel; Beate Schultheis; Michael Schatz; Christian Lorentz; Junia V Melo; Rüdiger Hehlmann; Andreas Hochhaus; Paul La Rosée
Journal:  Haematologica       Date:  2007-06       Impact factor: 9.941

Review 9.  Chronic myeloid leukaemia as a model of disease evolution in human cancer.

Authors:  Junia V Melo; David J Barnes
Journal:  Nat Rev Cancer       Date:  2007-06       Impact factor: 60.716

10.  Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.

Authors:  Heather A Bradeen; Christopher A Eide; Thomas O'Hare; Kara J Johnson; Stephanie G Willis; Francis Y Lee; Brian J Druker; Michael W Deininger
Journal:  Blood       Date:  2006-06-13       Impact factor: 22.113

View more
  42 in total

1.  DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma.

Authors:  Christopher M Cabello; Sarah D Lamore; Warner B Bair; Angela L Davis; Sara M Azimian; Georg T Wondrak
Journal:  Free Radic Res       Date:  2010-11-01

2.  Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.

Authors:  Chiara Corrado; Anna Maria Flugy; Simona Taverna; Stefania Raimondo; Giuliana Guggino; Rashida Karmali; Giacomo De Leo; Riccardo Alessandro
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

3.  SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.

Authors:  Qiangui Bu; Lijing Cui; Juan Li; Xin Du; Waiyi Zou; Ke Ding; Jingxuan Pan
Journal:  Cancer Biol Ther       Date:  2014-04-23       Impact factor: 4.742

4.  Novel use of old drug: Anti-rheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cells.

Authors:  Xin Chen; Xianping Shi; Xuejun Wang; Jinbao Liu
Journal:  Cancer Cell Microenviron       Date:  2014-11-01

5.  Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein.

Authors:  Li Yin; Rehan Ahmad; Michio Kosugi; Takeshi Kawano; David Avigan; Richard Stone; Surender Kharbanda; Donald Kufe
Journal:  Cancer Biol Ther       Date:  2010-09-04       Impact factor: 4.742

Review 6.  Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.

Authors:  Kush Patel; Zainab So Ahmed; Xuemei Huang; Qianqian Yang; Elmira Ekinci; Christine M Neslund-Dudas; Bharati Mitra; Fawzy Aem Elnady; Young-Hoon Ahn; Huanjie Yang; Jinbao Liu; Qing Ping Dou
Journal:  Future Med Chem       Date:  2018-08-01       Impact factor: 3.808

7.  Metabolic reprogramming orchestrates cancer stem cell properties in nasopharyngeal carcinoma.

Authors:  Yao-An Shen; Chia-Yu Wang; Yi-Tao Hsieh; Yann-Jang Chen; Yau-Huei Wei
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

8.  Effective killing of leukemia cells by the natural product OSW-1 through disruption of cellular calcium homeostasis.

Authors:  Celia Garcia-Prieto; Kausar Begam Riaz Ahmed; Zhao Chen; Yan Zhou; Naima Hammoudi; Ying Kang; Changgang Lou; Yan Mei; Zhendong Jin; Peng Huang
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

Review 9.  Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.

Authors:  Mary E Irwin; Nilsa Rivera-Del Valle; Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2012-09-28       Impact factor: 8.401

Review 10.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.